Secondary Analysis on Malaria RDTs in WHO Product Testing from Round 5 to 8 on False Negative Results in Testing Sample

Abstract Background with the widespread use of malaria rapid diagnostic tests (RDTs) in clinical practice, they also show their own challenges. Compared with most of the attention focusing on false positive results in WHO product testing, the same important false negative results attract insufficient focus. Method data of 129 malaria RDTs in the summary of WHO rounds 5 to 8 product testing was secondary analyzed in 5 aspects including low parasite density, improper RDTs storage, operation and interpretation, P. falciparum (Pf) with pfhrp2/3 genes deletion, inter-lot variation. Results First, the percentage of tests that achieved a panel detection score (PDS) < 80% at a low parasite density was 20-25% for Pf, and substantially higher for P. vivax (Pv). Second, Some Pv- and Pf- detecting products showed an increasing deterioration with increase of storage temperature. Third, approximately 20-27% products’ performances were unsatisfied in blood safety and instruction quality; and 30-35% test bands of the RDTs for Pf were barely visible, and the ones for Pv returned a higher proportion of weak band intensity. Fourth, different Lots of each test products may produce inconsistent results. Fifth, many malaria RDTs obtained a low PDS (< 50%) and a high false negative rate (> 50%) when testing Pf with deletion of pfhrp2/3 gene. Conclusion the malaria RDTs currently widely used were overestimated and could cause false negative results in practice. The clinicians should be aware of these shortcomings in order to draw more accurate diagnosis and treatment.